Markets & Finance

Needham Keeps Buy on Rigel Pharmaceuticals


Needham reiterated the buy rating on Rigel Pharmaceuticals (RIGL).

Analyst Mark Monane says positive data results will enable Rigel to move on to late-stage testing and secure a collaborative partnership for its allergy treatment R112 in the near future. He says the data is clinically meaningful and supports his thesis that R112 is a "nonsteroid steroid."

Monane notes the rapid onset of action and effect on nasal congestion seen with R112 are two beneficial effects typically not seen with intranasal steroids. In anticipation of continued positive news flow in the third and fourth quarters, given Rigel's solid fundamentals, he believes the current valuation is very attractive.

Monane sees a $2.58 2004 loss and a $2.75 2005 loss. He has a $33 target.


Coke's Big Fat Problem
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus